(Q63400709)
Statements
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDOTIXN® in Subject With Benign Masseteric Hypertrophy (English)
0 references
9 April 2018
0 references
31 August 2019
0 references
180
0 references
20 year
0 references
65 year
0 references